—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Viatris Inc (VTRS) — chart, structure and Closelooknet read

The Closelooknet read

Viatris is a healthcare company that sells prescription brand drugs, generics, complex generics and biosimilars across four regional units covering North America, Europe, Greater China and emerging markets. It supplies treatments spanning cardiovascular, diabetes, oncology, respiratory and other therapeutic areas, and distributes through wholesalers, pharmacies and specialty channels.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for VTRS, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 47/100 · S&P 500 fund at 48, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-06
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 60th percentile of the window, -22.8% over 20 sessions. Factor regime → 2026-11-06
  • Sovereign pressure Index -1.91 · down 2.45 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-06
How it trades on rate days beta 0.56 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How VTRS has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.56 — tends to move with bonds for every 1% move in TLT (20+ year Treasuries), Viatris Inc moved 0.56% on average · correlation 0.16 · higher than 48% of US names
  • Beta, last 3 months 0.50 about the same as over the year
  • On the 10 worst bond days −1.07% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +1.75% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - Specialty & Generic · United States · 5 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against VTRS on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Viatris Inc

VTRS in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Viatris is a healthcare company that sells prescription brand drugs, generics, complex generics and biosimilars across four regional units covering North America, Europe, Greater China and emerging markets. It supplies treatments spanning cardiovascular, diabetes, oncology, respiratory and other therapeutic areas, and distributes through wholesalers, pharmacies and specialty channels. It also runs collaboration deals with smaller biotech firms to develop and commercialise additional biosimilar products. The company is headquartered in Canonsburg, Pennsylvania, and formed from a merger of a generics business with a branded-drug unit spun out of a larger pharmaceutical company.
Where it sits in the stack
Viatris carries no seat in our AI build-out index; it belongs to the healthcare sector, within the generic and specialty pharmaceutical sleeve of our wider universe, and is not read against the compute stack.
Who it is priced against
The diary has no peer group set for this name; the comparison the market usually draws is with other multinational generics makers such as Teva.
Why Closelooknet tracks it
Viatris holds a seat in the S&P 500 but none in our own indices, carries no Closelooknet score yet, and has not been quoted in the diary's editions.
What the diary watches
Whether the recent lift in analyst price targets is followed by any change in the underlying earnings outlook, which the diary would treat as the more telling signal.

Viatris Inc (VTRS) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 4 analyst actions on the wire · latest: price target by Jefferies, 2026-11-06

The Street on this name

Analyst actions and the latest print for VTRS from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Jefferies — target 22 Target set to $22 (+16% to spot) 2026-11-06
  • Price target Piper Sandler — target 14 from 13 Target raised to $14 from $13 (-22.2% to spot) 2026-10-26
  • Price target Oppenheimer — target 25 Target set to $25 (+45.5% to spot) 2026-09-23

4 actions on the analyst wire since 2026-08-13: 4 target changes. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 2.41%, quarterly · last 0.12 USD on 2026-08-21

Dividends and capital return

What VTRS pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.48 USD per share · a 2.41% yield on the 2026-11-06 close 4 distributions, paid quarterly 2026-11-06
  • Change on the year 0.0% against the prior twelve months prior twelve months 0.48 USD per share
  • Last distribution 0.12 USD per share as the price series records it, within days of the ex-date 2026-08-21
  • By calendar year 2023: 0.12 USD (partial) · 2024: 0.48 USD · 2025: 0.48 USD · 2026: 0.36 USD to date first distribution recorded in the three-year window: 2023-11-22

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-07

Quick answers

What is Viatris Inc (VTRS)?

Viatris Inc trades as VTRS on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-11-07.

Is VTRS in a Closelooknet index?

Not currently — Viatris Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-07.

Where does VTRS trade against its moving averages?

Viatris Inc trades 12.5% above its 50-day and 24.6% above its 200-day moving average (7.4% above its 20-day). As of 2026-11-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Viatris Inc compare with its peers?

Against its peer group (Drug Manufacturers - Specialty & Generic · United States), Viatris Inc (VTRS) sits 0.3% below its 52-week high, 12.5% above its 50-day average; Neurocrine Biosciences Inc (NBIX) is 11.5% below, Elanco Animal Health (ELAN) is 8.0% below, Perrigo Company PLC (PRGO) is 5.7% below, as of 2026-11-06. Put any of them next to VTRS in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Viatris Inc trade when bond yields rise?

Over the past year Viatris Inc had a beta of 0.56 to TLT, the long-dated Treasury fund — it tends to move with bonds, higher than 48% of US names. On the 10 sessions in which long bonds fell most it moved −1.07% on average, against −0.74% for the S&P 500. As of 2026-11-06; The "How it trades on rate days" block on this page carries the lines.

What does Viatris Inc do?

Viatris is a healthcare company that sells prescription brand drugs, generics, complex generics and biosimilars across four regional units covering North America, Europe, Greater China and emerging markets. It supplies treatments spanning cardiovascular, diabetes, oncology, respiratory and other therapeutic areas, and distributes through wholesalers, pharmacies and specialty channels. It also runs collaboration deals with smaller biotech firms to develop and commercialise additional biosimilar products. The diary has no peer group set for this name; the comparison the market usually draws is with other multinational generics makers such as Teva. (Company snapshot of 2026-09-17.)

Where does Viatris Inc sit in the AI build-out?

Viatris carries no seat in our AI build-out index; it belongs to the healthcare sector, within the generic and specialty pharmaceutical sleeve of our wider universe, and is not read against the compute stack. Viatris holds a seat in the S&P 500 but none in our own indices, carries no Closelooknet score yet, and has not been quoted in the diary's editions. (Company snapshot of 2026-09-17.)

Does Viatris Inc pay a dividend?

Viatris Inc has paid 0.48 USD per share over the last twelve months, paid quarterly, a trailing yield of 2.41% on the 2026-11-06 close; the last distribution recorded in the price series was 0.12 USD on 2026-08-21. As of 2026-11-06; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Viatris Inc recently?

The most recent analyst action on Viatris Inc on the Closelooknet wire is a price target by Jefferies on 2026-11-06 (target 22). 4 actions on the analyst wire since 2026-08-13: 4 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for VTRS, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.